SC 13G - ELUTIA INC. (0001708527) (Subject)

SC 13G/A - ELUTIA INC. (0001708527) (Subject)

4 - ELUTIA INC. (0001708527) (Issuer)

4 - ELUTIA INC. (0001708527) (Issuer)

4 - ELUTIA INC. (0001708527) (Issuer)

4 - ELUTIA INC. (0001708527) (Issuer)

4 - ELUTIA INC. (0001708527) (Issuer)

4 - ELUTIA INC. (0001708527) (Issuer)

4 - ELUTIA INC. (0001708527) (Issuer)

4 - ELUTIA INC. (0001708527) (Issuer)

4 - ELUTIA INC. (0001708527) (Issuer)

4 - ELUTIA INC. (0001708527) (Issuer)

Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: First Commercial Use: Announced the first patient implant of EluPro, the FDA-cleared antibiotic-eluting biologic envelope for pacemakers and neurostimulators.Strong Initial Adoption: EluPro is being utilized across all major cardiac implantable electronic device (CIED) brands and in neurostimulation procedures. EluPro now accounts

SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, Matt Ferguson, Chief Financial Officer, and Dr. Michelle LeRoux Williams, Chief Scientific Officer, will participate in 1x1 investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024. Institutional investors interested in meeting with management during the conference may reach out to their Canaccord representative. About ElutiaElutia develops and commercializes drug-eluting biom

SILVER SPRING, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a leader in drug-eluting biomatrix products, today announced that it will release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information. Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13749386 Please log in approximately 10 minutes prior to the scheduled start time. A l

SILVER SPRING, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XVII Conference in Los Angeles on Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET). LD Micro Main Event XVII ConferencePresentation Date: Wednesday, October 30, 2024Presentation Time: 2:00 p.m. PT (5:00 p.m. ET)Webcast: Click here Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro representative or email [email protected]. About Eluti

Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results

EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model SILVER SPRING, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a leader in drug-eluting biomatrix products, today announced the publication of preclinical data demonstrating that EluPro, the world's first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA), clears bacterial contamination associated with cardiovascular implantable electronic devices (CIEDs). Data published in Frontiers in Drug Delivery show that in an animal model, EluPro demonstrated the ability to reduce bacterial coloniz

Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, is celebrating its one-year anniversary and the team that made it possible. On September 6, 2023, as part of a strategic shift toward drug-eluting biologics, the company rebranded as Elutia Inc. and established the mission of "Humanizing Medicine so Patients can Thrive without Compromise." The following day, the company began trading on Nasdaq under the new ticker symbol "ELUT." In its first year as Elutia, the company achieved several significant milestones a

SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world's first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac Electrophysiology Fellowship at East Carolina University Health Medical Center in Greenville, North Carolina. "We are honored to be the first facility to implant EluPro," said Dr. Cata

SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York: H.C. Wainwright 26th Annual Global Investment ConferenceFormat: Presentation and 1x1 MeetingsPresentation Date and Time (On-demand beginning): Monday, September 9, 2024, 7:00 a.m. ET 1x1 Meetings: Wednesday, September 11, 2024Webcast: Click here Lake Street Capital Markets 8th Annual Best Ideas Growth ConferenceFormat: 1x1 MeetingsDate: Thursday, September

MIAMI, Aug. 21, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-8200Sales@QuoteM

SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries. "We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Operations," said Dr. Randy Mills, Elutia's Chief Executive Officer. "At Elutia, culture matters, and Ryan has both the experience and character to make him an excellent fit and an effectiv

Lake Street analyst Frank Takkinen maintains Elutia (NASDAQ:ELUT) with a Buy and raises the price target from $5 to $10.

Cantor Fitzgerald analyst Ross Osborn maintains Elutia (NASDAQ:ELUT) with a Overweight and raises the price target from $5 to $11.

Cantor Fitzgerald analyst Ross Osborn maintains Elutia (NASDAQ:ELUT) with a Overweight and raises the price target from $5 to $11.

Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 35.9% to $0.14. The company's market cap stands at $2.4 million. Venus Concept (NASDAQ:VERO) stock increased by 22.86% to $1.15. The company's market cap stands at $7.3 million. Tharimmune (NASDAQ:THAR) shares moved upwards by 19.4% to $4.0. The company's market cap stands at $3.1 million. TRACON Pharma (NASDAQ:TCON) stock moved upwards by 19.04% to $1.5. The market value of their outstanding shares is at $4.0 million. Kineta (NASDAQ:KA) shares moved upwards by

EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market EluPro also granted clearance for indications beyond CIEDs, including neurostimulators and neuromodulators used for pain management, epilepsy, incontinence, and sleep apnea

Gainers Elutia (NASDAQ:ELUT) stock rose 24.2% to $4.31 during Tuesday's regular session. The market value of their outstanding shares is at $104.9 million. Trinity Biotech (NASDAQ:TRIB) stock rose 20.61% to $2.75. The company's market cap stands at $26.0 million. Akari Therapeutics (NASDAQ:AKTX) shares moved upwards by 20.26% to $3.03. The company's market cap stands at $35.5 million. Kronos Bio (NASDAQ:KRON) shares increased by 16.71% to $1.11. The market value of their outstanding shares is at $66.7 million. Black Diamond Therapeutic (NASDAQ:BDTX) shares increased by 15.72% to $5.91. The market value of their outstanding shares is at $332.7 million. Streamline Health Solns (NASDAQ:ST

Cantor Fitzgerald analyst Ross Osborn maintains Elutia (NASDAQ:ELUT) with a Overweight and lowers the price target from $6 to $5.

Elutia (NASDAQ:ELUT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.41) by 82.93 percent. This is a 222.95 percent decrease over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $6.694 million which beat the analyst consensus estimate of $6.100 million by 9.74 percent. This is a 4.72 percent increase over sales of $6.392 million the same period last year.

4/A - ELUTIA INC. (0001708527) (Issuer)